Entrada Therapeutics

TRDAPhase 2

Entrada Therapeutics is focused on transforming the treatment of devastating diseases by enabling the intracellular delivery of therapeutic molecules. The company's core Endosomal Escape Vehicle (EEV) platform facilitates the delivery of proteins, peptides, oligonucleotides, and other cargo into the cytoplasm of target cells, opening new avenues for treating conditions with intracellular targets. Entrada has advanced multiple programs into clinical development, secured strategic partnerships with major pharmaceutical companies, and operates as a publicly traded entity on NASDAQ. The company's mission is to leverage its platform to create a broad pipeline of novel therapeutics for patients with high unmet medical needs.

Market Cap

$433.0M

Employees

100-200

Focus

Biotech

TRDA · Stock Price

USD 11.31+1.07 (+10.45%)

Historical price data

AI Company Overview

Technology Platform

Proprietary Endosomal Escape Vehicle (EEV) platform, a cyclic cell-penetrating peptide technology designed to deliver therapeutic cargo (oligonucleotides, proteins, peptides) into the cytoplasm of target cells.

Pipeline Snapshot

2 drugs in pipeline

Drug	Indication	Stage
ENTR-601-44 + ENTR-601-44 - matching placebo	Duchenne Muscular Dystrophy (DMD)	Phase 1/2
ENTR-601-45 + ENTR-601-45 - matching placebo	Duchenne Muscular Dystrophy (DMD)	Phase 1/2

Opportunities

The EEV platform's ability to deliver diverse cargo intracellularly opens vast opportunities beyond lead DMD programs, including other neuromuscular, metabolic, and CNS disorders.

Successful clinical validation could lead to lucrative new partnerships and pipeline expansion.

The significant unmet need in DMD and other rare diseases presents a clear path for market penetration and growth.

Risk Factors

Lead clinical programs may fail to demonstrate efficacy or an acceptable safety profile.

Intense competition in the DMD space requires demonstrating clear superiority over existing therapies.

The company is pre-revenue and dependent on capital markets and partnership milestones to fund operations.

Competitive Landscape

Primary competitors in DMD exon skipping are Sarepta Therapeutics and NS Pharma. In the broader intracellular delivery space, competitors include Dyne Therapeutics, Avidity Biosciences, and PepGen. Entrada aims to differentiate through the superior endosomal escape efficiency of its proprietary cyclic peptide EEV platform.

Publications

Patents

Pipeline